Discounted Cash Flow (DCF) Analysis Unlevered
Onconova Therapeutics, Inc. (ONTX)
$0.7254
-0.00 (-0.44%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 1.23 | 2.18 | 0.23 | 0.23 | 0.23 | 0.22 | 0.21 | 0.20 | 0.19 | 0.18 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -24.88 | -21.76 | -24.79 | -16.82 | -19.63 | -12.88 | -12.29 | -11.72 | -11.18 | -10.67 |
| EBITDA (%) | ||||||||||
| EBIT | -24.93 | -21.78 | -24.80 | -16.83 | -19.64 | -12.89 | -12.30 | -11.73 | -11.19 | -10.68 |
| EBIT (%) | ||||||||||
| Depreciation | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | 16.97 | 22.73 | 19.03 | 55.07 | 38.76 | 22.50 | 21.46 | 20.47 | 19.53 | 18.63 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | 0.04 | 0.10 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | 4.04 | 4.27 | 4.83 | 2.76 | 3.86 | 2.39 | 2.28 | 2.18 | 2.08 | 1.98 |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | - | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.7,254 |
|---|---|
| Beta | 1.766 |
| Diluted Shares Outstanding | 20.91 |
| Cost of Debt | |
| Tax Rate | 3.50 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 12.961 |
| Total Debt | - |
| Total Equity | 15.17 |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 1.23 | 2.18 | 0.23 | 0.23 | 0.23 | 0.22 | 0.21 | 0.20 | 0.19 | 0.18 |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -24.88 | -21.76 | -24.79 | -16.82 | -19.63 | -12.88 | -12.29 | -11.72 | -11.18 | -10.67 |
| EBIT | -24.93 | -21.78 | -24.80 | -16.83 | -19.64 | -12.89 | -12.30 | -11.73 | -11.19 | -10.68 |
| Tax Rate | -0.19% | -0.05% | -0.02% | 2.07% | 3.50% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% |
| EBIAT | -24.98 | -21.79 | -24.80 | -16.48 | -18.95 | -12.76 | -12.17 | -11.61 | -11.07 | -10.56 |
| Depreciation | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Accounts Receivable | - | -0.06 | 0.06 | 0.01 | -0 | 0.01 | 0 | 0 | 0 | 0 |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | 0.23 | 0.56 | -2.08 | 1.10 | -1.47 | -0.11 | -0.11 | -0.10 | -0.10 |
| Capital Expenditure | - | -0.06 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| UFCF | -24.93 | -21.66 | -24.18 | -18.55 | -17.85 | -14.22 | -12.28 | -11.71 | -11.17 | -10.66 |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | |||||
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -10.87 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -38.76 |
| Equity Value | - |
| Shares Outstanding | 20.91 |
| Equity Value Per Share | - |